Literature DB >> 26071613

Aneurysmal degeneration of the thoracoabdominal aorta after medical management of type B aortic dissections.

Christopher A Durham1, Nathan J Aranson1, Emel A Ergul1, Linda J Wang1, Virendra I Patel1, Richard P Cambria1, Mark F Conrad2.   

Abstract

BACKGROUND: Patients with uncomplicated type B aortic dissections who are managed medically are at risk of aortic aneurysmal degeneration over time. However, the effect of improvement in antihypertensive medications and stricter blood pressure control is unknown. The goal of this study was to determine the rate of aneurysmal degeneration in a contemporary cohort of patients with medically treated type B dissection.
METHODS: Included were all patients with acute uncomplicated type B aortic dissection who were initially managed medically between March 1999 and March 2011 and had follow-up axial imaging studies. Maximum aortic growth was calculated by comparing the initial imaging study to the most current scan or imaging obtained just before any aortic-related intervention. An increase of ≥5 mm was the threshold considered as aortic growth. Predictors of aortic aneurysmal degeneration were determined using Cox proportional hazards models.
RESULTS: We identified 200 patients (61% men) with medically managed acute type B dissections receiving multiple imaging studies. Patients were an average age of 63.4 years, and 75.5% had a history of hypertension. Mean follow-up was 5.3 years (range, 0.1-14.7 years). Mean time between the initial and final imaging studies was 3.2 years (range, 0.1-12.9 years). At 5 years, only 51% were free from aortic growth. Fifty-six patients (28%) required operative intervention (50 open, 6 endovascular repair) for aneurysmal degeneration, and the actuarial 5-year freedom from intervention was 76%. After excluding five patients (2.5%) with early rapid degeneration requiring intervention within the first 2 weeks, the mean rate of aortic growth was 12.3 mm/y for the total aortic diameter, 3.8 mm/y for the true lumen diameter, and 8.6 mm/y for the false lumen diameter. Only aortic diameter at index presentation >3.5 cm was a risk factor for future growth (odds ratio, 2.54; 95% confidence interval, 1.34-4.81; P < .01). Complete thrombosis of the false lumen was protective against growth (odds ratio, 0.19; 95% confidence interval, 0.11-0.42; P < .01).
CONCLUSIONS: Although medical management of uncomplicated acute, type B aortic dissections has been the standard of care, at 5 years, a significant number of patients will require operative intervention for aneurysmal degeneration. Further studies of early intervention (eg, thoracic endovascular aortic repair) for type B aortic dissection to prevent late aneurysm formation are needed.
Copyright © 2015 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26071613     DOI: 10.1016/j.jvs.2015.04.423

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  11 in total

Review 1.  Treatment of uncomplicated type B aortic dissection.

Authors:  Hitoshi Matsuda
Journal:  Gen Thorac Cardiovasc Surg       Date:  2016-12-05

Review 2.  How should we manage type B aortic dissections?

Authors:  J Fleerakkers; M Schepens
Journal:  Gen Thorac Cardiovasc Surg       Date:  2017-08-29

3.  Left ventricular hypertrophy is a possible biomarker for early mortality after type B aortic dissection.

Authors:  Alexander P Taylor; Rosario V Freeman; Matthew A Bartek; Sherene Shalhub
Journal:  J Vasc Surg       Date:  2018-12-11       Impact factor: 4.268

4.  Predictors of Long-Term Aortic Growth and Disease Progression in Patients with Aortic Dissection, Intramural Hematoma, and Penetrating Aortic Ulcer.

Authors:  Francesco Squizzato; Meredith C Hyun; Indrani Sen; Mario D'Oria; Thomas Bower; Gustavo Oderich; Jill Colglazier; Randall R DeMartino
Journal:  Ann Vasc Surg       Date:  2021-11-14       Impact factor: 1.607

5.  Population-Based Assessment of the Incidence of Aortic Dissection, Intramural Hematoma, and Penetrating Ulcer, and Its Associated Mortality From 1995 to 2015.

Authors:  Randall R DeMartino; Indrani Sen; Ying Huang; Thomas C Bower; Gustavo S Oderich; Alberto Pochettino; Kevin Greason; Manju Kalra; Jill Johnstone; Fahad Shuja; W Scott Harmsen; Thanila Macedo; Jay Mandrekar; Alanna M Chamberlain; Salome Weiss; Philip P Goodney; Veronique Roger
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2018-08

6.  Aortic visceral segment instability is evident following thoracic endovascular aortic repair for acute and subacute type B aortic dissection.

Authors:  Juliet Blakeslee-Carter; Hellen A Potter; Charles A Banks; Marc Passman; Benjamin Pearce; Graeme McFarland; Sukgu M Han; Salvatore Scali; Gregory A Magee; Emily Spangler; Adam W Beck
Journal:  J Vasc Surg       Date:  2022-03-08       Impact factor: 4.860

7.  Role of Re-entry Tears on the Dynamics of Type B Dissection Flap.

Authors:  Saranya Canchi; Xiaomei Guo; Matt Phillips; Zachary Berwick; Jarin Kratzberg; Joshua Krieger; Blayne Roeder; Stephan Haulon; Sean Chambers; Ghassan S Kassab
Journal:  Ann Biomed Eng       Date:  2017-10-30       Impact factor: 3.934

8.  Favorable remodeling after hybrid arch debranching and modified provisional extension to induce complete attachment technique in type a aortic dissection: A case report.

Authors:  Arkadiusz Kazimierczak; Tomasz Jedrzejczak; Paweł Rynio; Szymon Waligórski
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.817

9.  The new indication of TEVAR for uncomplicated type B aortic dissection.

Authors:  Chao Song; Qingsheng Lu; Jian Zhou; Guanyu Yu; Xiang Feng; Zhiqing Zhao; Junmin Bao; Rui Feng; Zaiping Jing
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889

10.  One-Year Single-Center Results of the Multilayer Flow Modulator Stents for the Treatment of Type B Aortic Dissection.

Authors:  Victor S Costache; Jorn P Meekel; Andreea Costache; Tatiana Melnic; Cristian Bucurenciu; Anca Chitic; Gabriela Candea; Crina Solomon; Kak K Yeung
Journal:  J Endovasc Ther       Date:  2020-09-01       Impact factor: 3.487

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.